Tyligand Bioscience Ltd. has identified new GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Tyk Medicines Inc. has patented new cyclin-dependent kinase 2 (CDK2) and/or cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of cancer, infections, metabolic diseases, cardiovascular, inflammatory and immunological disorders.

Several Gluetacs Therapeutics (Shanghai) Co. Ltd. patents describe molecular glue degraders reported to be useful for the treatment of cancer, anemia, liver failure, diabetes, infections, sarcoidosis, autoimmune diseases and cardiovascular disorders.

Muna Therapeutics ApS has disclosed new potassium voltage-gated channel subfamily A member 3 (KCNA3, Kv1.3) channel blockers reported to be useful for the treatment of cancer, neurodegeneration, cardiovascular, gastrointestinal, immunological, inflammatory, metabolic and renal disorders, among others.

Enanta Pharmaceuticals Inc. has discovered mast/stem cell growth factor receptor kit (KIT; c-KIT; CD117) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis, pulmonary arterial hypertension, irritable bowel syndrome, inflammatory, dermatological and respiratory disorders, among others.

The Brigham and Women's Hospital Inc., Massachusetts General Hospital and UCL Business Ltd. have jointly patented new benzo[c][l,2,5]thiadiazolyl compounds and radiolabeled derivatives targeting α-synuclein, amyloid-β (Aβ) protein and microtubule-associated protein tau.

Work at Greenstone Biosciences Inc. has led to the identification of dihydroartemisinin derivatives reported to be useful for the treatment of fibrosis.

Tuojie Biotech (Shanghai) Co. Ltd. has prepared oxygen-containing fused tricyclic derivatives acting as CDK2/cyclin E1 and/or CDK4/cyclin D1 inhibitors. As such, they are reported to be potentially useful for the treatment of cancer, infections, autoimmune disease and inflammatory disorders.

Xaicure Pharmaceuticals (Suzhou) Co. Ltd. has described histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) and/or histone acetyltransferase KAT6B (MOZ2; MYST-4) inhibitors reported to be useful for the treatment of cancer.

Maze Therapeutics Inc. has divulged apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, diabetic retinopathy, diabetic HIV-associated nephropathy, lupus nephritis, pre-eclampsia and sepsis.